Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()

The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Jiménez, Alejandro, Rubio-Romero, Esteban, Fuente, José Luis Marenco de la
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041148/
https://www.ncbi.nlm.nih.gov/pubmed/32482538
http://dx.doi.org/10.1016/j.reumae.2020.04.012
_version_ 1783677887678775296
author Muñoz-Jiménez, Alejandro
Rubio-Romero, Esteban
Fuente, José Luis Marenco de la
author_facet Muñoz-Jiménez, Alejandro
Rubio-Romero, Esteban
Fuente, José Luis Marenco de la
author_sort Muñoz-Jiménez, Alejandro
collection PubMed
description The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infection.
format Online
Article
Text
id pubmed-8041148
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.
record_format MEDLINE/PubMed
spelling pubmed-80411482021-04-13 Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19() Muñoz-Jiménez, Alejandro Rubio-Romero, Esteban Fuente, José Luis Marenco de la Reumatol Clin (Engl Ed) Special Article The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infection. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021 2021-04-12 /pmc/articles/PMC8041148/ /pubmed/32482538 http://dx.doi.org/10.1016/j.reumae.2020.04.012 Text en © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Special Article
Muñoz-Jiménez, Alejandro
Rubio-Romero, Esteban
Fuente, José Luis Marenco de la
Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
title Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
title_full Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
title_fullStr Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
title_full_unstemmed Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
title_short Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
title_sort proposal for the use of anakinra in acute respiratory distress secondary to covid-19()
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041148/
https://www.ncbi.nlm.nih.gov/pubmed/32482538
http://dx.doi.org/10.1016/j.reumae.2020.04.012
work_keys_str_mv AT munozjimenezalejandro proposalfortheuseofanakinrainacuterespiratorydistresssecondarytocovid19
AT rubioromeroesteban proposalfortheuseofanakinrainacuterespiratorydistresssecondarytocovid19
AT fuentejoseluismarencodela proposalfortheuseofanakinrainacuterespiratorydistresssecondarytocovid19

Ejemplares similares